Discovering a pelvic mass can be scary and overwhelming experience. Download this guide to help settle those fears by better understanding what you’re facing and taking action with OVA1.
OVA1 is the best option for early detection.
Having risk factors doesn’t guarantee a diagnosis. It simply means you may have a greater chance of developing the disease. Learn more about how OVA1, Vermillion’s first-generation Multivariate Index Assay (MIA), is improving ovarian cancer detection.
Patient Education: Ovarian Cancer Testing
Benefits of OVA1
Historically, physicians have utilized the CA-125 as a blood test to evaluate the likelihood of ovarian cancer in patients. While there are no FDA-cleared ovarian cancer screening tests available, OVA1 (MIA) was developed to be better than CA-125 alone at detecting all types of ovarian cancer in patients with a pelvic mass scheduled for surgery. OVA1 (MIA) is highly sensitive meaning a low-risk patient should be managed by their obstetrician/ gynecologist or an elevated-risk patient should be referred to a gynecologic oncologist for surgical treatment. Your OVA1 (MIA) score determines if your mass is at lower risk for ovarian cancer or at a higher risk. Patients with elevated cancer risk may benefit from treatment by a gynecologic oncologist who specializes in the diagnosis and treatment of cancer in the reproductive organs. If cancer is present, getting to a specialist for the first surgery increases a woman’s chance of survival up to 40 percent.
Patients appropriate for referral to a gynecologic oncologist may benefit from:
- Effective surgery and treatment
- Timely medical management
- Improved survival rate and outcomes
Historically, physicians have utilized the CA-125 as a blood test to evaluate the likelihood of ovarian cancer in patients. OVA1 (MIA) was developed to be better than CA-125 alone at detecting all types of ovarian cancer. Ask your physician to order OVA1.
If you have a planned adnexal mass surgery, are experiencing ovarian cancer symptoms and you would like to have an OVA1 (MIA) test performed, please bring an ASPiRA LABS’ test request form with the patient portion completed to your healthcare provider. Your healthcare provider will help assess if OVA1 (MIA) is right for you and guide you through the next steps.
OVA1 has been tested across the country by providers and women with positive outcomes.